KLOW Protocol
The GLOW stack (BPC-157 + TB-500 + GHK-Cu) plus the anti-inflammatory tripeptide KPV -- a four-peptide blend aimed at tissue repair with an added anti-inflammatory component.
Evidence-led profile
Research snapshot
- Evidence stage
- Emerging research
- References
- 5 linked sources
- Editorial review
- Jul 7, 2026
Published by the PepGuide Editorial Team using our research methodology.
Overview
The 'KLOW' protocol is a four-peptide blend -- essentially the GLOW stack with KPV added (the leading K denotes KPV):
- BPC-157 -- pentadecapeptide that accelerates soft-tissue and gut healing, largely via VEGF-driven angiogenesis (Chang et al., 2019; Brcic et al., 2009).
- TB-500 -- thymosin beta-4 fragment that promotes cell migration, angiogenesis and wound repair (Philp et al., 2004).
- GHK-Cu -- copper tripeptide that stimulates collagen, elastin and glycosaminoglycan synthesis and skin remodeling (Pickart, 2008).
- KPV -- the tripeptide Lys-Pro-Val, the C-terminal fragment of alpha-melanocyte-stimulating hormone, with anti-inflammatory activity. It is transported into cells via PepT1 and suppresses NF-kB-driven inflammation independent of melanocortin receptors, reducing intestinal and tissue inflammation in models (Dalmasso et al., 2008).
The added rationale over GLOW is an explicit anti-inflammatory arm: KPV is intended to calm the inflammatory environment while the other three peptides drive vascularisation, cell recruitment and matrix rebuilding.
Typical stack dosing (research-community practice, not clinically validated): often a once-daily subcutaneous injection providing roughly BPC-157 250-500 mcg, TB-500 250-500 mcg, GHK-Cu 1-2 mg and KPV 250-500 mcg, run in multi-week cycles. KPV is also used orally for gut-directed effects given its PepT1-mediated uptake. These figures derive from the individual peptides' preclinical literature and community protocols; none of the components is FDA-approved and the blend has no controlled human trial data.
Safety and Limitations
Safety Profile: KLOW Protocol
Common Side Effects
- Individual component side effects: the KLOW protocol combines multiple peptides and compounds; side effects reflect the additive profile of each constituent
- Injection site reactions: redness, swelling, pain, and itching at subcutaneous injection sites
- Fatigue and flu-like symptoms, particularly during initial protocol phases
- Headache and mild gastrointestinal discomfort (nausea, bloating)
- Water retention and transient edema
- Sleep disturbances (insomnia or excessive drowsiness depending on components)
Serious Adverse Effects
- Compounded hormonal disruption: multi-peptide protocols may unpredictably alter hormonal axes (GH/IGF-1, hypothalamic-pituitary-gonadal, thyroid)
- Immunological reactions: risk increases with multiple injectable peptides; includes severe allergic reactions and antibody formation against peptide components
- Cardiovascular risk: cumulative effects of multiple growth-promoting peptides may increase cardiac hypertrophy risk and insulin resistance
- Tumor promotion: theoretical concern that stacking growth factor–stimulating peptides may promote growth of undiagnosed malignancies
- No peer-reviewed clinical trials exist for the combined KLOW protocol; all safety inferences are extrapolated from individual component data
Contraindications
- Active malignancy or history of cancer (growth-promoting peptides may stimulate tumor growth)
- Uncontrolled diabetes or insulin resistance (multiple components may worsen glycemic control)
- Cardiovascular disease including heart failure, uncontrolled hypertension, or history of cardiac hypertrophy
- Pregnancy or lactation (multi-peptide hormonal effects are unpredictable)
- Autoimmune conditions (immune-modulating peptides may trigger flares)
- Hepatic or renal impairment (clearance of multiple peptides may be compromised)
Drug Interactions
- Insulin and oral hypoglycemics: growth hormone–stimulating components may antagonize glucose control
- Anticoagulants: some peptide components may affect coagulation parameters
- Immunosuppressants: immune-modulating peptides may counteract immunosuppressive therapy
- Thyroid medications: protocol components may alter thyroid hormone metabolism
- Corticosteroids: may blunt efficacy of growth hormone–releasing peptides
- Complex polypharmacy risk: interactions between protocol components themselves are poorly characterized
Population-Specific Considerations
- Pregnancy/Lactation: strictly contraindicated; hormonal effects of stacked peptides are unpredictable and potentially teratogenic
- Children/Adolescents: not appropriate; developing endocrine systems are vulnerable to multi-axis hormonal manipulation
- Elderly: increased cardiovascular and metabolic risk; multi-peptide protocols require careful cardiac and metabolic monitoring
- Athletes: many components may be prohibited by WADA and sports anti-doping agencies
- General: this is a non-FDA-approved stacking protocol; medical supervision is essential; no standardized dosing or safety monitoring guidelines exist
Mechanism of Action
The three regenerative peptides supply vascularisation (BPC-157 via VEGF/NO; TB-500 via actin-driven endothelial migration) and extracellular-matrix rebuilding (GHK-Cu). KPV adds transporter-mediated intracellular anti-inflammatory signalling: accumulating in epithelial and immune cells through PepT1, it suppresses NF-kB and reduces neutrophil infiltration and cytokine expression, an effect shown for intestinal inflammation and proposed to benefit gut- and skin-directed uses of the stack.
References (5)
- [1]Chang CH, Tsai WC, Hsu YH, Pang JS Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing International Journal of Molecular Sciences (2019)
→ Review of BPC-157's preclinical role in accelerating healing of tendon, ligament and muscle soft tissue.
- [2]Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing Journal of Physiology and Pharmacology (2009)
→ BPC-157 promotes angiogenesis during muscle and tendon healing via upregulation of VEGF expression.
- [3]Philp D, Goldstein AL, Kleinman HK Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development Mechanisms of Ageing and Development (2004)
→ Thymosin beta-4 (the parent of TB-500) promotes angiogenesis, cell migration and wound repair in normal and aged animals.
- [4]Pickart L The human tri-peptide GHK and tissue remodeling Journal of Biomaterials Science, Polymer Edition (2008)
→ GHK-Cu supports tissue remodeling, stimulating collagen, elastin and glycosaminoglycan synthesis while modulating inflammation.
- [5]Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Gastroenterology (2008)
→ The alpha-MSH-derived tripeptide KPV is taken up via PepT1 and reduces intestinal inflammation by inhibiting NF-kB signalling, independent of melanocortin receptors.
Continue researching KLOW Protocol
Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.